ReAlta Life Sciences

ReAlta Life Sciences is a private, pre-revenue biotech founded in 2018 and based in Norfolk, Virginia, USA. The company is advancing pegtarazimod, a dual-targeting anti-inflammatory peptide, with a lead Phase 2 program in neonatal HIE, a devastating condition with no approved disease-modifying therapies. Its platform aims to broadly address inflammatory diseases by targeting upstream drivers (complement and neutrophils), supported by an experienced leadership team including the original scientific discoverers. ReAlta represents a high-risk, high-reward opportunity in the niche but critical area of neonatal neurology and inflammation.

Peptide-based platform targeting both the complement cascade and neutrophil activation, derived from astrovirus evolutionary biology, to provide upstream control of inflammation.

In neonatal HIE, ReAlta's pegtarazimod faces little direct competition from other late-stage pharmacologic therapies, with therapeutic hypothermia being the standard of care. However, the broader complement therapeutic space is competitive with several approved drugs and candidates from larger biopharma companies for other indications.